Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – SunTrust Banks issued their Q1 2020 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a note issued to investors on Sunday, March 22nd. SunTrust Banks analyst J. Lee forecasts that the biopharmaceutical company will post earnings per share of $0.09 for the quarter. SunTrust Banks also issued estimates for Catalyst Pharmaceuticals’ Q2 2020 earnings at $0.11 EPS, Q3 2020 earnings at $0.11 EPS and Q4 2020 earnings at $0.11 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Monday, March 16th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.02). The company had revenue of $30.12 million during the quarter, compared to analyst estimates of $30.00 million. Catalyst Pharmaceuticals had a net margin of 31.16% and a return on equity of 45.52%.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Catalyst Pharmaceuticals in a research note on Monday, December 23rd. BidaskClub cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 29th. Cantor Fitzgerald increased their price target on Catalyst Pharmaceuticals from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, ValuEngine raised Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, March 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $8.95.

Shares of CPRX stock opened at $3.82 on Wednesday. The stock has a market cap of $369.17 million, a price-to-earnings ratio of 13.17 and a beta of 2.28. The stock has a 50-day moving average of $4.10 and a 200-day moving average of $4.61. The company has a current ratio of 4.62, a quick ratio of 4.54 and a debt-to-equity ratio of 0.01. Catalyst Pharmaceuticals has a 1-year low of $2.23 and a 1-year high of $7.67.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in Catalyst Pharmaceuticals during the third quarter worth approximately $27,000. Meeder Asset Management Inc. grew its stake in Catalyst Pharmaceuticals by 91.4% during the fourth quarter. Meeder Asset Management Inc. now owns 6,492 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 3,100 shares during the period. Virtu Financial LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $40,000. Sei Investments Co. acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $48,000. Finally, 9258 Wealth Management LLC acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $50,000. 60.77% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

See Also: What Does a Sell-Side Analyst Rating Mean?

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.